NCT06033612View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

July 27, 2022

Study Completion Date

July 27, 2022

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

RV299

Oral Suspension

DRUG

Placebo

matching placebo

DRUG

Midazolam

pre-filled oral syringe

Trial Locations (1)

SE1 1YR

Richmond Pharmacology Ltd, London

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06033612 - Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults | Biotech Hunter | Biotech Hunter